European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 20 October 2010 AT 4.15 PM
EET
Orion Corporation has submitted a marketing authorisation application for the
intensive care sedative agent dexmedetomidine for the evaluation by the European
Medicines Agency (EMA), the pharmaceutical regulatory authority for the EU
countries. EMA has announced today that it has validated the centralised
marketing authorisation application and initiated the review. The review time
for a centralised marketing authorisation application typically exceeds one
year.
Orion Corporation
Timo Lappalainen Reijo Salonen
President and CEO SVP, Research and Development
Contact person:
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
[HUG#1453555]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 20.10.2010 - 15:08 Uhr
Sprache: Deutsch
News-ID 45955
Anzahl Zeichen: 0
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
